Centessa Pharmaceuticals plc
CNTA
$16.51
-$0.495-2.91%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 15.00M | 15.00M | -- | 6.85M | 6.85M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.00M | 15.00M | -- | 6.85M | 6.85M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 15.00M | 15.00M | -- | 6.85M | 6.85M |
| SG&A Expenses | 50.45M | 49.71M | 50.81M | 49.42M | 48.94M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 221.42M | 210.74M | 201.06M | 168.51M | 162.31M |
| Operating Income | -206.42M | -195.74M | -201.06M | -161.65M | -155.46M |
| Income Before Tax | -226.54M | -220.09M | -232.91M | -158.33M | -157.84M |
| Income Tax Expenses | 3.83M | 3.76M | 2.84M | 2.94M | -496.00K |
| Earnings from Continuing Operations | -230.37 | -223.85 | -235.76 | -161.27 | -157.35 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -230.37M | -223.85M | -235.76M | -161.27M | -157.35M |
| EBIT | -206.42M | -195.74M | -201.06M | -161.65M | -155.46M |
| EBITDA | -205.80M | -195.12M | -200.41M | -160.99M | -154.79M |
| EPS Basic | -1.78 | -1.81 | -1.99 | -1.52 | -1.56 |
| Normalized Basic EPS | -0.94 | -0.95 | -1.06 | -0.92 | -0.96 |
| EPS Diluted | -1.78 | -1.81 | -1.99 | -1.52 | -1.56 |
| Normalized Diluted EPS | -0.94 | -0.95 | -1.06 | -0.92 | -0.96 |
| Average Basic Shares Outstanding | 515.02M | 490.83M | 457.68M | 423.55M | 403.95M |
| Average Diluted Shares Outstanding | 515.02M | 490.83M | 457.68M | 423.55M | 403.95M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |